{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:06:45Z","timestamp":1794049605808,"version":"4.8.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.euroneuro.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T01:31:06Z","timestamp":1652146266000},"page":"58-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7774-1585","authenticated-orcid":false,"given":"Caroline MB","family":"Kwee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna MP","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Febe E","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-7796","authenticated-orcid":false,"given":"Lucianne","family":"Groenink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0076-003X","authenticated-orcid":false,"given":"Puck","family":"Duits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4934-6427","authenticated-orcid":false,"given":"Merijn","family":"Eikelenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Date C","family":"van der Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-1237","authenticated-orcid":false,"given":"Mirjam","family":"Moerbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6444-3781","authenticated-orcid":false,"given":"Neeltje M","family":"Batelaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9171-0208","authenticated-orcid":false,"given":"Anton JLM","family":"van Balkom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle C","family":"Cath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2022.04.003_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pnpbp.2012.10.024","article-title":"Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test","volume":"41","author":"Almeida","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0002","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J. Consult. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0003","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr. Drug. Saf."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0004","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0005","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of \u03b4-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0006","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0007","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.euroneuro.2008.07.001","article-title":"Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats","volume":"18","author":"Bitencourt","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0008","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0009","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/hmg\/ddh216","article-title":"Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use","volume":"13","author":"Chiang","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brat.2014.04.006","article-title":"Maximizing exposure therapy: an inhibitory learning approach","volume":"58","author":"Craske","year":"2014","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0012","first-page":"417","volume":"29","author":"Crippa","year":"2004","journal-title":"Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.euroneuro.2022.04.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20603","article-title":"Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial","volume":"4","author":"Crippa","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0014","doi-asserted-by":"crossref","first-page":"300 309","DOI":"10.1002\/cpt1976193300","article-title":"Influence of cannabidiol on delta-9-tetrahydrocannabinol effects","volume":"19","author":"Dalton","year":"1976","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","article-title":"Cannabidiol enhances consolidation of explicit fear extinction in humans","volume":"226","author":"Das","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0016","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbr.2013.04.045","article-title":"Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors","volume":"250","author":"Do Monte","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/da.22353","article-title":"Updated meta-analysis of classical fear conditioning in the anxiety disorders","volume":"32","author":"Duits","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0020","series-title":"Structured Clinical Interview For DSM-IV-TR Axis I disorders, Research version, Patient edition. (SCID-I\/P). Biometrics Research","author":"First","year":"2002"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0021","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of A9-Tetrahydrocannabinol and cannabidiol on neural activation during emotional processing","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0022","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/mp.2012.72","article-title":"Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity","volume":"18","author":"Gunduz-Cinar","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0023","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/tp.2012.90","article-title":"Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1","volume":"2","author":"Heitland","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0024","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0025","first-page":"531","article-title":"No Effects of d-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: a Double-Blind, Randomized Controlled Trial","volume":"37","author":"Hofmeijer-Sevink","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0026","series-title":"Multilevel analysis: Techniques and Applications","author":"Hox","year":"2018"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0027","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejpb.2020.06.021","article-title":"Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers","volume":"154","author":"Izgelov","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0028","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fphar.2016.00454","article-title":"Cannabidiol regulation of learned fear: implications for treating anxiety-related disorders","volume":"7","author":"Jurkus","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1152\/physrev.00019.2008","article-title":"Endocannabinoid-mediated control of synaptic transmission","volume":"89","author":"Kano","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbr.2009.09.045","article-title":"Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats","volume":"207","author":"Lemos","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0031","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2019","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0032","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0005-7967(79)90041-X","article-title":"Brief standard self-rating for phobic patients","volume":"17","author":"Marks","year":"1979","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0033","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature00839","article-title":"The endogenous cannabinoid system controls extinction of aversive memories","volume":"418","author":"Marsicano","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0034","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders","volume":"10","author":"Masataka","year":"2019","journal-title":"Front. Psychol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0035","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0196-9781(00)00324-7","article-title":"Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study","volume":"21","author":"Moldrich","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0036","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.pnpbp.2006.06.004","article-title":"Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test","volume":"30","author":"Moreira","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0037","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00213-004-1825-7","article-title":"Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine induced and amphetamine-induced conditioned place preference learning in rats","volume":"175","author":"Parker","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0038","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbr.2006.05.016","article-title":"Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats","volume":"172","author":"Resstel","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0039","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jad.2012.10.031","article-title":"Recurrence of anxiety disorders and its predictors","volume":"147","author":"Scholten","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fnbeh.2019.00091","article-title":"The divergent effects of CDPPB and cannabidiol on fear extinction and anxiety in a predator scent stress model of PTSD in rats","volume":"13","author":"Shallcross","year":"2019","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0041","doi-asserted-by":"crossref","first-page":"e8792","DOI":"10.1371\/journal.pone.0008792","article-title":"Biomarkers of endocannabinoid system activation in severe obesity","volume":"5","author":"Sipe","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0042","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.janxdis.2012.02.010","article-title":"Non-adherence and non-response in the treatment of anxiety disorders","volume":"26","author":"Taylor","year":"2012","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0043","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.biopsych.2012.12.009","article-title":"d-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia","volume":"73","author":"Smits","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0044","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fphar.2016.00493","article-title":"Bidirectional effects of cannabidiol on contextual fear memory extinction","volume":"7","author":"Song","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0009-3084(00)00190-0","article-title":"The fatty acid amide hydrolase (FAAH)","volume":"108","author":"Ueda","year":"2000","journal-title":"Chem. Phys. Lipids."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0046","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12888-019-2022-x","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial","volume":"19","author":"Van der Flier","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0047","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamapsychiatry.2019.3986","article-title":"Long-term outcomes of cognitive behavioral therapy for anxiety-related disorders: a systematic review and meta-analysis","volume":"66","author":"Van Dis","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0048","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/bcp.13529","article-title":"Integrating data from the Investigational Medicinal Product Dossier\/investigator's brochure. A new tool for translational integration of preclinical effects","volume":"84","author":"Van Gerven","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0049","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety","volume":"7","author":"Zuardi","year":"1993","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.04.003_bib0051","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2017.00259","article-title":"Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life","volume":"8","author":"Zuardi","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:02:35Z","timestamp":1760378555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22001699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"alternative-id":["S0924977X22001699"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.04.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}